Takeda Treads Carefully With DPP-4 Late-Arrival Nesina, Plans Summer Launch
Executive Summary
Takeda’s beleaguered Nesina (alogliptin) becomes the fourth DPP-4 inhibitor approved by FDA for diabetes; it remains to be seen whether the drug can find its place in a highly competitive space that continues to be controlled by Merck’s first-to-market blockbuster Januvia.
You may also be interested in...
Takeda’s Global Ambitions Focus On Crohn’s, Cancer – And Churn
Three product launches in U.S. last year, including Entyvio, showcase its expansion strategy, but first non-Japanese CEO could be biggest shift for firm.
Diabetes, Asthma Portfolios Would Suit Risk-Sharing Contracts – Express Scripts
Express Scripts exec Steve Miller discussed how the pharmacy benefit manager would respond to manufacturers offering comprehensive portfolios of drugs in the diabetes and asthma segments.
Alogliptin, Saxagliptin Show Neutral CV Effects In Outcomes Studies
In separate trials, Takeda’s Nesina and BMS/AstraZeneca’s Onglyza demonstrated neither cardiovascular benefit nor harm in type 2 diabetics at increased risk for such events. The DPP-4 inhibitors also were not associated with increased rates of pancreatitis, which has been a safety concern for the class.